Crossmark

Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years

Crossref DOI link: https://doi.org/10.1016/j.eimc.2025.503056

Published Print: 2026-02

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Amador, Concha

Ambrosioni, Juan

Martín-Carbonero, Luz

Hidalgo-Tenorio, Carmen

Tiraboschi, Juan

Moreno, Santiago
Funding

Funding for this research was provided by:

ViiV Healthcare

Gilead Sciences Inc
License Information

Text and Data Mining valid from 2026-02-01

Text and Data Mining valid from 2026-02-01

Version of Record valid from 2025-12-05
More Information

This article is maintained by: Elsevier

Article Title: Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years

Journal Title: Enfermedades Infecciosas y Microbiología Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eimc.2025.503056

Content Type: article

Copyright: © 2025 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.